Nov 14,2022

AI In Medical Imaging Market Worth $8.18 Billion By 2030: Grand View Research, Inc.

The global AI in medical imaging market size is expected to reach USD 8.18 billion by 2030, based on a new report. The market is expected to expand at a CAGR of 34.7% from 2022 to 2030 owing to the growing aging population and increased investment in the healthcare ecosystem by government and private players. The breast screening segment is anticipated to expand at the fastest CAGR of 41.5% during the forecast period owing to the rising demand for breast screening procedures due to the growing incidence rate of breast cancer in women.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

API Platform to Enable Jasper Health to Generate More Advanced Patient Insights and Elevate Customized Cancer Care

Announced today, Jasper Health and Particle Health, an integrations and API platform that has modernized the health data experience for healthcare companies, have partnered to generate enhanced health data insights to augment personalized cancer care support. Access to actionable shared health data allows clinicians and Jasper care coaches to identify barriers to healthcare and provide curated health insights relevant to members and their specific health needs. Particle Health’s API complements Jasper Health’s existing clinical data integrations to leverage meaningful health data to improve cancer care support and delivery, and elevate members’ experience, quality of life, and outcomes.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 14,2022

COTA and Google Partner to Use Natural Language Processing to Harness Unstructured Data

Finding a way to consistently and accurately extract unstructured data is one of the top goals for technologists, including a newly formed team of machine learning experts at COTA, Google, John Snow Labs, and Quantiphi. Together, the partners are using breakthroughs in machine learning and natural language processing (NLP) to extract unstructured data elements from EHRs to fuel innovation in oncology research and treatment.

COLLABORATION PARTNERSHIP

#data & technology

#ml

#rwd

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Perspectives of older women with early breast cancer on telemedicine during post-primary treatment

Telemedicine has the potential to lessen healthcare burden of older patients due to frequent appointments, physical disabilities, and reliance on caretakers. To benefit from telemedicine, patients must have the capacity and willingness to engage with technology. This study aimed to better understand the telemedicine experiences of older women with non-metastatic breast cancer regarding visit convenience, completeness, and interpersonal satisfaction.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Massive Bio and Azra AI to Expand AI’s Potentially Lifesaving Impact on Cancer Patients

Massive Bio announced a strategic partnership with Azra AI, a healthcare technology company that uses proprietary AI software to identify cancer diagnoses in real time and accelerate the patient care process. Where Azra AI focuses on identification of cancer, Massive Bio’s platform provides cancer patients with relevant clinical trials using AI, empowering patients to find treatment options faster and enabling life sciences companies to conduct broader, more-inclusive, population-based recruitment rather than traditional site-specific recruitment. Combined with Massive Bio’s ability to surface personalized clinical trial options for patients, the two companies working together provide early identification and precise treatment options, further improving cancer clinical care.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 16,2022

Lunit to Supply AI Platform to Australia's BreastScreen NSW Machine Reading Project

Lunit, a leading medical AI provider serving over 1,000 sites around the world, today announced that it has signed a contract to supply its AI solution for the BreastScreen NSW State program, managed by the Cancer Institute NSW (New South Wales' cancer control agency). Lunit's selection as the program's supplier marks the first case globally in which an AI-based solution is being deployed by a national cancer screening organization.

PRODUCT

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 21,2022

Jasper Health Hosts Panel on Disparities in Cancer Care

Jasper Health sponsored a panel at the Advancing Healthcare Innovation Summit featuring digital health and oncology professionals to discuss the presence of disparities in oncology and cancer care, and how patient-first solutions and psychosocial support help bridge the gaps.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 22,2022

Novartis highlights scientific advances in upcoming conferences

Novartis will present data on the latest advancements in breast cancer and hematology at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, and the American Society of Hematology (ASH) Annual Meeting, December 10-13. More than 130 abstracts, from both Novartis-sponsored trials and investigator-initiated trials using Novartis compounds, were accepted at the meetings, reinforcing Novartis leadership and innovation in priority oncology therapeutic areas.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 22,2022

AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022

AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), 6-10 December 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 23,2022

GNS Announces Abstract and Oral Poster Presentation at CTAD & ASH, 2022 Annual Conferences

GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY